Residual pulmonary hypertension in children after treatment with inhaled nitric oxide: A follow-up study regarding cardiopulmonary and neurological symptoms

S. Göthberg, K. E. Edberg, Swee Fong Tang, S. Michelsen, P. Winberg, D. Holmgren, O. Miller, E. Thaulow, P. A. Lönnqvist

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Inhaled nitric oxide is a potent vasodilator in acute severe pulmonary hypertension and is increasingly used as rescue treatment in intensive care algorithms aiming at reducing severe hypoxaemia in neonates and children. Although the immediate effects may seem impressive, long-term outcome regarding residual pulmonary hypertension and other sequelae has been studied in only a very few patients. The aim of the present study was to evaluate residual pulmonary hypertension, cardiopulmonary or neurological symptoms in children after treatment with inhaled nitric oxide in severely hypoxaemic and/or pulmonary hypertensive mechanically ventilated children. The study was performed in four paediatric intensive care units in university hospitals in Sweden, Norway and Australia. Patients who had received inhaled nitric oxide as part of their intensive care treatment for severe hypoxaemia and/or pulmonary hypertension, and in whom 6 mo had elapsed since treatment, were included for evaluation. Thus 36 paediatric or neonatal patients were examined for circulatory, respiratory or neurological disorders with clinical examination, echocardiography, chest X-ray and a capillary blood sample. Four patients with congenital heart disease had residual pulmonary hypertension. Nine patients were receiving bronchodilators. Sixteen patients had minor (n = 15) or moderate (n = 1) changes on a chest X-ray. One patient had a possible delay in psychomotor development. Conclusions: In spite of the severity of their primary illness, we found that the overwhelming majority of the surviving children were asymptomatic and doing well. The few residual circulatory and respiratory symptoms could be related to the initial condition.

Original languageEnglish
Pages (from-to)1414-1419
Number of pages6
JournalActa Paediatrica, International Journal of Paediatrics
Volume89
Issue number12
DOIs
Publication statusPublished - 2000
Externally publishedYes

Fingerprint

Pulmonary Hypertension
Nitric Oxide
Critical Care
Therapeutics
Thorax
X-Rays
Pediatric Intensive Care Units
Bronchodilator Agents
Norway
Nervous System Diseases
Vasodilator Agents
Sweden
Echocardiography
Heart Diseases
Newborn Infant
Pediatrics
Lung

Keywords

  • Acute respiratory failure
  • Children
  • Congenital heart defect
  • Follow-up
  • Inhaled nitric oxide
  • Pulmonary hypertension

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Residual pulmonary hypertension in children after treatment with inhaled nitric oxide : A follow-up study regarding cardiopulmonary and neurological symptoms. / Göthberg, S.; Edberg, K. E.; Tang, Swee Fong; Michelsen, S.; Winberg, P.; Holmgren, D.; Miller, O.; Thaulow, E.; Lönnqvist, P. A.

In: Acta Paediatrica, International Journal of Paediatrics, Vol. 89, No. 12, 2000, p. 1414-1419.

Research output: Contribution to journalArticle

Göthberg, S. ; Edberg, K. E. ; Tang, Swee Fong ; Michelsen, S. ; Winberg, P. ; Holmgren, D. ; Miller, O. ; Thaulow, E. ; Lönnqvist, P. A. / Residual pulmonary hypertension in children after treatment with inhaled nitric oxide : A follow-up study regarding cardiopulmonary and neurological symptoms. In: Acta Paediatrica, International Journal of Paediatrics. 2000 ; Vol. 89, No. 12. pp. 1414-1419.
@article{0399aa6e75ae4d40b5222960adecfdfd,
title = "Residual pulmonary hypertension in children after treatment with inhaled nitric oxide: A follow-up study regarding cardiopulmonary and neurological symptoms",
abstract = "Inhaled nitric oxide is a potent vasodilator in acute severe pulmonary hypertension and is increasingly used as rescue treatment in intensive care algorithms aiming at reducing severe hypoxaemia in neonates and children. Although the immediate effects may seem impressive, long-term outcome regarding residual pulmonary hypertension and other sequelae has been studied in only a very few patients. The aim of the present study was to evaluate residual pulmonary hypertension, cardiopulmonary or neurological symptoms in children after treatment with inhaled nitric oxide in severely hypoxaemic and/or pulmonary hypertensive mechanically ventilated children. The study was performed in four paediatric intensive care units in university hospitals in Sweden, Norway and Australia. Patients who had received inhaled nitric oxide as part of their intensive care treatment for severe hypoxaemia and/or pulmonary hypertension, and in whom 6 mo had elapsed since treatment, were included for evaluation. Thus 36 paediatric or neonatal patients were examined for circulatory, respiratory or neurological disorders with clinical examination, echocardiography, chest X-ray and a capillary blood sample. Four patients with congenital heart disease had residual pulmonary hypertension. Nine patients were receiving bronchodilators. Sixteen patients had minor (n = 15) or moderate (n = 1) changes on a chest X-ray. One patient had a possible delay in psychomotor development. Conclusions: In spite of the severity of their primary illness, we found that the overwhelming majority of the surviving children were asymptomatic and doing well. The few residual circulatory and respiratory symptoms could be related to the initial condition.",
keywords = "Acute respiratory failure, Children, Congenital heart defect, Follow-up, Inhaled nitric oxide, Pulmonary hypertension",
author = "S. G{\"o}thberg and Edberg, {K. E.} and Tang, {Swee Fong} and S. Michelsen and P. Winberg and D. Holmgren and O. Miller and E. Thaulow and L{\"o}nnqvist, {P. A.}",
year = "2000",
doi = "10.1080/080352500456561",
language = "English",
volume = "89",
pages = "1414--1419",
journal = "Acta Paediatrica, International Journal of Paediatrics",
issn = "0803-5253",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - Residual pulmonary hypertension in children after treatment with inhaled nitric oxide

T2 - A follow-up study regarding cardiopulmonary and neurological symptoms

AU - Göthberg, S.

AU - Edberg, K. E.

AU - Tang, Swee Fong

AU - Michelsen, S.

AU - Winberg, P.

AU - Holmgren, D.

AU - Miller, O.

AU - Thaulow, E.

AU - Lönnqvist, P. A.

PY - 2000

Y1 - 2000

N2 - Inhaled nitric oxide is a potent vasodilator in acute severe pulmonary hypertension and is increasingly used as rescue treatment in intensive care algorithms aiming at reducing severe hypoxaemia in neonates and children. Although the immediate effects may seem impressive, long-term outcome regarding residual pulmonary hypertension and other sequelae has been studied in only a very few patients. The aim of the present study was to evaluate residual pulmonary hypertension, cardiopulmonary or neurological symptoms in children after treatment with inhaled nitric oxide in severely hypoxaemic and/or pulmonary hypertensive mechanically ventilated children. The study was performed in four paediatric intensive care units in university hospitals in Sweden, Norway and Australia. Patients who had received inhaled nitric oxide as part of their intensive care treatment for severe hypoxaemia and/or pulmonary hypertension, and in whom 6 mo had elapsed since treatment, were included for evaluation. Thus 36 paediatric or neonatal patients were examined for circulatory, respiratory or neurological disorders with clinical examination, echocardiography, chest X-ray and a capillary blood sample. Four patients with congenital heart disease had residual pulmonary hypertension. Nine patients were receiving bronchodilators. Sixteen patients had minor (n = 15) or moderate (n = 1) changes on a chest X-ray. One patient had a possible delay in psychomotor development. Conclusions: In spite of the severity of their primary illness, we found that the overwhelming majority of the surviving children were asymptomatic and doing well. The few residual circulatory and respiratory symptoms could be related to the initial condition.

AB - Inhaled nitric oxide is a potent vasodilator in acute severe pulmonary hypertension and is increasingly used as rescue treatment in intensive care algorithms aiming at reducing severe hypoxaemia in neonates and children. Although the immediate effects may seem impressive, long-term outcome regarding residual pulmonary hypertension and other sequelae has been studied in only a very few patients. The aim of the present study was to evaluate residual pulmonary hypertension, cardiopulmonary or neurological symptoms in children after treatment with inhaled nitric oxide in severely hypoxaemic and/or pulmonary hypertensive mechanically ventilated children. The study was performed in four paediatric intensive care units in university hospitals in Sweden, Norway and Australia. Patients who had received inhaled nitric oxide as part of their intensive care treatment for severe hypoxaemia and/or pulmonary hypertension, and in whom 6 mo had elapsed since treatment, were included for evaluation. Thus 36 paediatric or neonatal patients were examined for circulatory, respiratory or neurological disorders with clinical examination, echocardiography, chest X-ray and a capillary blood sample. Four patients with congenital heart disease had residual pulmonary hypertension. Nine patients were receiving bronchodilators. Sixteen patients had minor (n = 15) or moderate (n = 1) changes on a chest X-ray. One patient had a possible delay in psychomotor development. Conclusions: In spite of the severity of their primary illness, we found that the overwhelming majority of the surviving children were asymptomatic and doing well. The few residual circulatory and respiratory symptoms could be related to the initial condition.

KW - Acute respiratory failure

KW - Children

KW - Congenital heart defect

KW - Follow-up

KW - Inhaled nitric oxide

KW - Pulmonary hypertension

UR - http://www.scopus.com/inward/record.url?scp=0034509976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034509976&partnerID=8YFLogxK

U2 - 10.1080/080352500456561

DO - 10.1080/080352500456561

M3 - Article

C2 - 11195228

AN - SCOPUS:0034509976

VL - 89

SP - 1414

EP - 1419

JO - Acta Paediatrica, International Journal of Paediatrics

JF - Acta Paediatrica, International Journal of Paediatrics

SN - 0803-5253

IS - 12

ER -